Peptide Therapeutics Market to Expand at a CAGR of 8.8% from 2022 to 2031

Peptide Therapeutics Market Outlook 2031

•          The global peptide therapeutics market was valued at US$ 39.34 Bn in 2021
•          The global market is projected to grow at a CAGR of 8.8% from 2022 to 2031
•          The global peptide therapeutics market is anticipated to reach more than US$ 91.25 Bn by 2031

Peptide Therapeutics Market Introduction

Peptides are a combination of two or more amino acid monomers linked by amide bonds. Researchers have demonstrated that peptides are distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered peptides. In addition to the current definition of peptide, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less.

Peptides bind to specific cell surface receptors and receptor ligands, and help in the treatment of diseases by acting on the cell membrane. Therapeutic proteins and peptides are a growing class of drugs intended for clinical purposes owning to high bio-specificity. As per the peptide therapeutics market analysis, demand for peptide therapeutics has been rising significantly due to the decline in non-peptide chemical drugs available in the market.

Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418

Impact of COVID-19 on Peptide Therapeutics market

The COVID-19 pandemic has had a positive impact on the global peptide therapeutics market growth. As of August 2022, 600 million infections and 6.4 million deaths were recorded across the world due to COVID-19. Peptide molecules are being used for the development of COVID-19 vaccine. Furthermore, government authorities of various countries have supported private players in the development and usage of COVID-19 vaccine.

More than 21 peptide drugs are being used for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection. Peptide drugs are being considered a treatment option for COVID-19. Thus, key players in the market have reported an increase in revenue during the COVID-19 pandemic. However, the application of peptide therapeutics in oncology, metabolic disorders, etc. has been disrupted due to a shortage of drugs and supply chain issues along with the slow progress of clinical trials related to non-COVID-19 therapeutics.

Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=418

Surge in Number of Cancer and Other Chronic Disease Patients to Drive Cancer Segment

In term of application, the cancer segment dominated the global market in 2021. Cancer is the leading cause of death globally. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2020. Chemotherapy, the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly, which negatively affects the normal cells in the body. Application of therapeutic peptides in cancer treatment has opened a promising avenue for future growth of the global peptide therapeutics market, as it has the ability to deliver drug with specific binding site. Peptide-based therapeutic vaccines have attracted attention as one of the effective treatments for tumor immunotherapy over the last few years. Rise in prevalence and incidence rate of other chronic conditions such as Alzheimer's, diabetes, cardiac diseases, and immune disorders, owing to the increase in geriatric population, is projected to propel the global peptide and Alzheimer's peptide therapeutics markets in the next few years.

Faster & Better Bioavailability and Quicker Onset Time Fueling Parenteral Segment

Based on route of administration, the global peptide therapeutics market has been classified into parenteral, oral, and others. The parenteral segment dominated the global peptide therapeutics market in 2021. Parenteral is the most common route of administration, as it ensures faster and better bioavailability, faster onset time, and better treatment outcomes. However, advancement in drug delivery technologies has led to a change in the trend of route of administration of therapeutic peptides.

Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=418

Minimal Waste and High Peptide Purity & Yield Bolstering Liquid Phase Segment

Based on technology, the liquid phase segment held the largest share of the global peptide therapeutics market in 2021. Liquid phase synthesis is usually favored for peptides, which have less than 15 amino acids by length. Liquid phase peptide synthesis provides economies of scale for the manufacturing of peptides. Minimal waste and high peptide purity and yield are the key advantages of this technology.

Usage in Drugs for Treatment of Cancer and Tumors Augmenting Immunopeptides Segment

In terms of type of molecule, the immunopeptide segment is likely to grow at a rapid pace during the forecast period owing to the rise in usage of immunopeptides in drugs for the treatment of cancer and tumors. High prevalence of cancer and surge in incidence rate of new cancer cases are likely to drive the immunopeptides segment during the forecast period.

Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=418

Stringent Quality Systems and Standards Requirements Driving In-house Segment

Based on API peptide type, the in-house segment dominated the global market in 2021. However, API manufacturers prefer to outsource peptides manufacturing to contract manufacturing organizations (CMOs) operating in the biosimilar market due to difficulties in manufacturing owing to the high quality standards implemented by regulatory authorities. For instance, Bachem and Peptisyntha provide end-to-end API peptides manufacturing, and possess expertise and high-end technology for various types of peptides. Nevertheless, the shift is likely to be gradual, as most API peptide companies still prefer to manufacture in-house due to stringent quality systems and standards requirements.

Regional Outlook of Global Peptide Therapeutics Market

North America is projected to dominate the global peptide therapeutics market during the forecast period. Well-established healthcare infrastructure, high priced peptide therapeutics drugs, and favorable reimbursement policies are augmenting the peptide therapeutics market growth in the region.

The market in Asia Pacific is anticipated to grow at a high CAGR during the forecast period due to the rise in prevalence of infectious diseases in the region. Increase in geriatric population and surge in healthcare expenditure are fueling the market in Asia Pacific. Furthermore, large patient pool and high demand for newer advanced therapies are key factors likely to boost the peptide therapeutics market in Asia Pacific.

Make an Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=418

Analysis of Key Players in Global Peptide Therapeutics market

The peptide therapeutics market report includes vital information about leading players in the global market. Companies are adopting product launch, divestiture, merger & acquisition, and partnership strategies to enhance their peptide therapeutics market share. Amgen, Inc., Bachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global market.